Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors01:13

Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors

364
Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
364
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

151
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
151
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

187
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
187
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

505
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
505
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents01:20

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

384
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
384

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Effectiveness and safety of first-line nivolumab-ipilimumab in metastatic renal cell carcinoma.

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners·2026
Same author

Economic impact of lung cancer clinical trials: Assessing cost savings in medication and testing.

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners·2026
Same author

[Translated article] OrPhar-SEFH 2024-2027 Strategic Plan.

Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria·2025
Same author

OrPhar-SEFH 2024-2027 Strategic Plan.

Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria·2025
Same author

Training program in compounding for pharmacy technicians through a digital platform and simulation techniques.

Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria·2024
Same author

Influence of rheumatoid factor levels and TNF inhibitor structure on secondary nonresponse in rheumatoid arthritis patients.

Frontiers in medicine·2024

相关实验视频

Updated: Jun 18, 2025

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

1.5K

质子抑制剂降低了乳腺转移患者的palbociclib的疗效.

Javier Álvarez Criado1, Pilar Zamora Auñon2, Virginia Martínez Marín2

  • 1Hospital Pharmacy Department, La Paz University Hospital, Madrid, Spain.

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
|August 2, 2024
PubMed
概括

同时使用质子抑制剂 (PPI) 在接受palbociclib的转移性乳腺癌 (mBC) 患者的无进展生存期 (PFS) 显著降低,特别是在一线设置中. 需要对个人保护药物进行进一步的研究.

关键词:
乳腺癌 乳腺癌 乳腺癌药物相互作用 药物相互作用这是palbocicliblib.质子抑制剂的使用

更多相关视频

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

13.2K
Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

8.7K

相关实验视频

Last Updated: Jun 18, 2025

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

1.5K
Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

13.2K
Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

8.7K

科学领域:

  • 在瘤学瘤学.
  • 药理学 药理学是指药理学的学科.

背景情况:

  • 激素受体阳性和HER2阴性转移性乳腺癌 (mBC) 是一个重大的临床挑战.
  • 帕尔博西克利布 (Palbociclib) 是一种关键疗法,但其疗效可能会受到并发药物的影响.
  • 质子抑制剂 (PPI) 通常用于胃肠道保护.

研究的目的:

  • 评估同时使用质子抑制剂 (PPI) 对激素受体阳性,HER2阴性转移性乳腺癌 (mBC) 患者的无进展生存期 (PFS) 的影响.
  • 为了比较在第一线和随后的治疗环境中接受palbociclib,并无同时服用PPI的患者之间的PFS.

主要方法:

  • 一项回顾性观察性研究包括165名ER+,HER2-mBC符合palbociclib治疗条件的ER+患者.
  • 患者根据PPI使用情况进行分类:并发 (≥2/3的palbociclib持续时间) 或没有并发的PPI.
  • 在两组之间分析了无进展生存期 (PFS).

主要成果:

  • 在一线设置中,同时使用PPI与PFS显著较短 (8.88个月) 与不使用PPI (67.81个月) 相比 (p < 0.0001).
  • 在二线或随后的设置中,同时使用PPI的患者的PFS为7.46个月,而没有PPI的PFS为17.29个月 (p = 0.122).
  • 观察到PPI对PFS的显著负面影响,特别是在使用palbociclib.mBC的第一线治疗中.

结论:

  • 同时使用PPI对接受palbociclib治疗的mBC患者的PFS产生负面影响,特别是在一线设置中.
  • 这些发现表明潜在的药物相互作用会影响palbociclib的疗效.
  • 需要进一步的研究来阐明PPI对CDK4/6抑制剂的机制和临床影响.